⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Travere Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Travere Therapeutics
↗San Diego, USA
Travere Therapeutics is a biopharmaceutical company dedicated to identifying, developing, and delivering life-changing therapies for people living with rare diseases. The company focuses on rare kidney and metabolic disorders, leveraging its platform to address conditions with significant unmet medical needs and small patient populations.
Headquartered in San Diego, the company has transitioned into a commercial-stage organization following the approval of its lead asset, FILSPARI (sparsentan). Travere emphasizes a patient-centered approach, integrating research, development, and commercial capabilities to support rare disease communities.
CLASSIFICATION
SIZE & FINANCIALS
Employees:201-500
Revenue:$100M-$500M
Ownership:public
Status:operating
STOCK
Exchange:NASDAQ
Ticker:TVTX
Market Cap:$4.1B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule
Trial Phases:-
FDA Approvals:2
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:CSL (Co-commercialization and international expansion for sparsentan)
COMPETITION
Position:Challenger
Competitors:Novartis, Calliditas Therapeutics
LEADERSHIP
Key Executives:
Not specified - CEO
LINKS
Website:travere.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Travere Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.